Cyberkrieg 2.0
Diese Tech-Aktie könnte Ihr Portfolio revolutionieren – und die nächste große Sicherheitslücke schließen
Anzeige
wert WKN: A407ZR ISIN: NL0015001ZQ0 Kürzel: AFMD Forum: Aktien User: value3000
2,525 EUR
-0,59 %-0,015
22. Nov, 10:39:48 Uhr,
L&S Exchange
Kommentare 26
v
value3000,
24.05.2024 22:31 Uhr
1
MANNHEIM, Germany, May 23, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that an update from the Company’s AFM24-102 study in advanced EGFR wild-type (EGFRwt) non-small cell lung cancer (NSCLC) will be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) to be held in Chicago on May 31 – June 4, 2024. Patients in the study are treated with the combination of AFM24, Affimed’s innate cell engager (ICE®), and atezolizumab, Roche’s checkpoint inhibitor (CPI).
As of the March 18 cut-off for the poster, 17 patients with EGFRwt NSCLC received the combination treatment and 15 patients were response evaluable. One patient showed a confirmed complete response, and three patients showed confirmed partial responses (PR). In addition, seven patients achieved stable disease, resulting in a disease control rate of 73.3% (11/15 patients). Median progression-free survival was 5.9 months.
All responders were resistant to checkpoint inhibitor treatment prior to the study, which supports the hypothesis that combining AFM24 with atezolizumab may enhance the cancer-immunity cycle and provide an alternative strategy to overcome resistance to existing therapies for EGFR-expressing tumors.
AFM24 and atezolizumab were given at their respective single agent doses. Treatment in these heavily pretreated patients was well tolerated. Side effects were consistent with the known safety profiles of these agents. The most frequent side effects observed were mild to moderate infusion related reactions and transient mild to moderate increase in liver enzymes.
“We are very encouraged to see objective and lasting responses in patients who have failed multiple lines of therapy including platinum doublets and checkpoint inhibitors,” said Dr. Andreas Harstrick, Chief Medical and acting Chief Executive Officer of Affimed. “These data support our hypothesis that the combination of AFM24 and PD-1 targeting may act synergistically on the immunity cycle. It is remarkable that this can be achieved with a chemotherapy-free approach. We are committed to continuing clinical development of this therapy and are enrolling additional patients for both EGFRwt and EGFRmut NSCLC.”
v
value3000,
23.05.2024 11:46 Uhr
1
Ich aktiviere hier mal einen neuen Thread..
Meistdiskutiert
|
Thema | ||
---|---|---|---|
1 | Dax Prognose | -0,65 % | |
2 | MicroStrategy | -8,71 % | |
3 | PAG911 | -1,64 % | |
4 | BAYER Hauptdiskussion | -0,92 % | |
5 | EVOTEC Hauptdiskussion | -2,08 % | |
6 | Trading- und Aktien-Chat | ||
7 | MICROSTRATEGY Hauptdiskussion | -8,71 % | |
8 | VW Hauptdiskussion | -1,55 % | |
9 | NVIDIA Hauptdiskussion | -0,28 % | |
10 | DAX Hauptdiskussion | -0,65 % | Alle Diskussionen |
Aktien
|
Thema | ||
---|---|---|---|
1 | MicroStrategy | -8,78 % | |
2 | PAG911 | -1,71 % | |
3 | BAYER Hauptdiskussion | -0,83 % | |
4 | EVOTEC Hauptdiskussion | -1,51 % | |
5 | MICROSTRATEGY Hauptdiskussion | -8,78 % | |
6 | VW Hauptdiskussion | -0,87 % | |
7 | NVIDIA Hauptdiskussion | -0,42 % | |
8 | ALIBABA GROUP ADR Hauptdiskussion | -2,51 % | |
9 | GAMESTOP Hauptdiskussion | +0,79 % | |
10 | ZUR ROSE GROUP AG SF5,75 Hauptdiskussion | +0,22 % | Alle Diskussionen |